NECTIN4 Amplifications Predict Outcomes in Metastatic Urothelial Cancer
WEDNESDAY, May 8, 2024-- For patients with metastatic urothelial cancer (mUC), NECTIN4 amplifications predict anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) response and outcomes, according to a study published online April 24 in the...